• Kazia Therapeutics will present two preclinical paxalisib studies at the San Antonio Breast Cancer Symposium, Dec. 8-11, 2026.
• Research suggests paxalisib reprograms tumor and immune biology differently from other dual PI3K/mTOR inhibitors across breast cancer subtypes.
• A second study explores potential suppression of local recurrence and metastatic progression following neoadjuvant chemo-immunotherapy in stage III triple-negative breast cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via CNW (Ref. ID: 202611020700CANADANWCANADAPR_C1516) on November 02, 2026, and is solely responsible for the information contained therein.